This week, CuraTeQ Biologics (a wholly owned step-down subsidiary of Aurobindo Pharma Limited) announced that its trastuzumab biosimilar, DAZUBLYS, has received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). DAZUBLYS, a 150 mg powder for concentrate for solution for infusion product, specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein as a treatment for certain solid cancers, such as breast and gastric cancer. According to the press release, this is the third biosimilar from the CuraTeQ portfolio to receive a positive opinion from CHMP in the last five months and the company aims to launch at least 10 biosimilars across oncology and immunology therapy by 2030.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
